Viking Therapeutics, Inc.

Novo Nordisk A/S

Eli Lilly and Company

Freedom Broker has issued a trade idea on the biotech Viking Therapeutics. The company is expected to present fresh data from clinical trials of its main weight-loss drug, and historically, as Freedom Broker points out, the stock rises ahead of these events.

Freedom Broker says buy weight-loss drugmaker Viking ahead of 2H data releases

DDC Enterprise Limited

Quotes for DayDayCook (DDC), which manufactures ready-to-heat, ready-to-cook, and ready-to-eat Asian food, <a href="https://finance.yahoo.com/quote/DDC/">soared</a>&nbsp;more than 53% yesterday, July 14, to a year-to-date high. The company <a href="https://ir.daydaycook.com/news-events/press-releases/detail/45/ddc-enterprise-launches-ddc-bitcoin-influence-collective-to-accelerate-growth-and-enhance-shareholder-value">announced</a>&nbsp;the launch of the "DDC Bitcoin Influence Collective" to bring together "top-tier thought leaders." Recently, DDC launched an "aggressive [bitcoin] accumulation strategy."&nbsp;

Gen Z-focused Asian food maker DDC makes new bitcoin treasury strategy move

Zimmer Biomet Holdings, Inc.

Shares of Monogram Technologies, a smaller company developing surgical robots to enable placement of patient optimized orthopedic implants, jumped 78% yesterday, July 14, hitting their highest mark since May 2023. The company <a href="https://finance.yahoo.com/news/zimmer-biomet-announces-definitive-agreement-113500570.html">announced</a>&nbsp;it would be acquired at a premium by medical device maker Zimmer Biomet. With the deal, Zimmer Biomet expects to become the first and only company in orthopedics to offer a fully autonomous surgical robot.

Surgical robot maker Monogram to be acquired by biotech Zimmer; stock soars 78%

Small caps are set to see more volatility in the second half of the year, according to a <a href="https://www.royceinvest.com/insights/royce-roundtable">roundtable discussion</a> of portfolio managers at Royce, which specializes in the small-cap space. The issue, they say, is that investors lack certainty about the policy backdrop.

Royce PMs see more volatility for small caps in 2H amid policy uncertainty

NIO Inc.

EVgo, Inc.

Navitas Semiconductor Corporation

The Motley Fool has <a href="https://www.fool.com/investing/2025/07/13/the-smartest-ev-stocks-to-buy-with-500-right-now/">recommended</a>&nbsp;three EV stocks.&nbsp;After booming in 2020-2021, the stocks of many industry players have fizzled out, but as contributor and analyst Leo Sun points out, "for investors who can look past those near-term headwinds [there might be] some promising plays."&nbsp;

Motley Fool highlights three EV stocks for when 'near-term headwinds' in sector pass

President Donald Trump’s so-called “Big Beautiful” bill, signed into law last week, extends tax incentives for smaller companies through 2030.

How Trump’s “Big Beautiful” tax law changes the game for smaller companies



The first half of 2025 proved to be a roller coaster for small-cap investors. Exchange-traded funds investing in European and Asian small caps delivered strong returns, while U.S.-focused peers largely hovered around flat performance or slipped into the red.

Small-cap ETF outperformers and underperformers in 1H25: Non-U.S. DMs ascendant

ProKidney Corp.

Biotech ProKidney, which develops a cell therapy platform for the treatment of multiple chronic kidney diseases, rose sixfold yesterday, July 8, to reach a market capitalization of $1.8 billion. The trigger was successful clinical trial results of its drug, but analysts are cautious.&nbsp;

Biotech ProKidney soars 500% after positive trial results, but analysts are cautious

A gauge of investor sentiment from Bloomberg Intelligence “approached manic” in June. This could portend a relative downturn in the small-cap space, however.

Why small-cap investors should be wary of 'manic' sentiment in markets

In recent years, South and Southeast Asia have attracted investors as a trove of new ideas and high-growth companies, with economies across the region undergoing rapid expansion and transformation. While investor attention often remains focused on large corporations, smaller firms in Asia are also delivering impressive growth and innovation, frequently achieving success within their respective niches. The MSCI Asia Apex Small Cap 200 index, which tracks the performance of the 200 largest and most liquid small caps in the broader MSCI AC Asia ex Japan Small Cap index, has soared 79.8% over the past three years and is up nearly 14.0% year to date. By comparison, the MSCI AC Asia Pacific index has risen 11.8% and 13.6% over the same periods, respectively.

Three small caps that reflect different aspects of Asia's growth and transformation

Beam Global

Beam Global CEO Desmond Wheatley brings more than three decades of executive experience to the table, having built and led companies ranging from startups to publicly traded firms generating $70 million in annual revenue, according to his LinkedIn <a href="https://www.linkedin.com/in/desmondwheatley/">profile</a>. “For a long time, I worked for companies that were polluting the environment. I spent a lot of time in the Middle East, working for people whose values I don't support now,” he said in an interview with Oninvest.

Head of clean tech innovator Beam Global tells Oninvest about plans and Trump effect


Hims & Hers Health, Inc.

Freedom Broker now recommends clients buy shares of Hims &amp; Hers Health, a telehealth company, in the wake of a recent dip. The mid-cap stock has lost 35% of its market value due to a canceled partnership with pharma giant Novo Nordisk, which alleges that Hims&nbsp;&amp; Hers put patient safety at risk through “deceptive” marketing and sold a knockoff version of its drug Wegovy. Despite this, Freedom Broker analysts think Hims &amp; Hers stock will bounce back quickly.&nbsp;